Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations

Tenofovir alafenamide (TAF) is a phosphonoamidate prodrug of the nucleotide HIV reverse transcriptase inhibitor tenofovir (TFV). TAF is approved for the treatment of HIV-1 infection as part of the single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and TAF. When dosed once-daily, TAF results in approximately 90% lower levels of plasma TFV and a 4-fold increase in intracell...

متن کامل

Clinically significant interaction between digoxin and quinidine.

paras), and to attend a clinic or return the questionnaire after three months. Fifty-two patients (87 %) (15 primiparas and 37 multiparas) completed questionnaires. They were matched with a control group of 52 vaccinated patients who received no hormonal treatment. The mean (i SD) number of days of postpartum bleeding was 58-5 i 18-5 in the treated patients and 20-8 1-1 in the controls. This di...

متن کامل

Important interaction between mirtazapine and ondansetron.

African Journal of Psychiatry • May 2012 160 Drug interaction in psychiatry is a clinically important issue, as it can cause side-effects and prevent adequate therapeutic effect. We report an unexpected interaction between the antidepressant mirtazapine and the antiemetic ondansetron in a 72 year old patient, weighing 68 kg, with a height of 173 cm. The patient, who gave his informed consent fo...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Pharmacology Research & Perspectives

سال: 2017

ISSN: 2052-1707

DOI: 10.1002/prp2.353